(RTTNews) - Shares of Inovio Pharmaceuticals Inc. (INO) are up 18% in pre-market today, continuing a spectacular rally of more than 60% yesterday. We alerted readers to this stock, just before it opened at $5.12 and the stock closed at $7.45 marking a 45.5% gain from the opening price, and a 70% gain from the previous close.
The company, on March 3, announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infection the World Health Organization (WHO) has designated a Public Health Emergency of International Concern of the highest level.
Dr. Joseph Kim, Inovio's President & CEO, shared this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on March 2. Dr. Kim said, "Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19."
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
